Will Testosterone Replacement Therapy Lose Weight?
Whether or not testosterone replacement therapy is an effective method for weight loss is a matter of debate. There are many factors that play a role in determining the amount of weight that can be lost. This includes the amount of fat and muscle mass that can be lost, as well as the metabolic parameters and insulin resistance that can be affected.
Using testosterone replacement therapy in elderly obese men can reduce fat mass and increase muscle mass. While testosterone is beneficial, there are some risks associated with this therapy. Specifically, testosterone replacement therapy may increase the risk of cardiovascular adverse events.
The primary purpose of this study was to determine the effects of testosterone on muscle strength and body composition in older, healthy men. The testosterone group decreased fat mass by 4.31 +- 1.63% at six months, and the placebo group increased fat mass by 4.21 +- 1.13% at six months. These changes were independent of age, body mass index, and nutritional status.
Reduces fat mass
Despite testosterone’s benefits, it may be attenuated when used in the context of a rigorous weight loss program. A study published by Dr. Mark Ng Tang Fui, an endocrinologist from the University of Melbourne, has shown that testosterone replacement therapy is effective at reducing fat mass and maintaining muscle mass in obese men.
Researchers randomly assigned a group of 100 obese men to receive intramuscular testosterone undecanoate for 10 weeks. After free guide , both groups had lost 11 kg (24.2 lb). Among the testosterone group, the fat mass loss was more than the placebo group.
Improves metabolic parameters
Using testosterone replacement therapy to improve metabolic parameters can benefit men with hypogonadism and type 2 diabetes. It is believed that testosterone helps improve insulin sensitivity, which will lead to reduced risk of cardiovascular disease.
In addition, testosterone can also help reduce symptoms of prostate inflammation, including lower urinary tract symptoms. It has also been found to decrease total cholesterol in men with coronary artery disease. This therapy has been shown to decrease fasting plasma glucose and insulin.
Improves insulin resistance
Several studies show that testosterone replacement therapy can reduce insulin resistance and improve glycemic control in men with type 2 diabetes. The hormone improves insulin sensitivity by increasing the body’s ability to absorb glucose. This leads to an increase in lean muscle mass and a decrease in fat tissue.
There is evidence that low testosterone levels in male adolescents may be a risk factor for insulin resistance. Men with type 2 diabetes are twice as likely to have low testosterone levels as men without diabetes. This suggests that insulin resistance may be a key component in the development of diabetes.
Improves glycemic control
Several studies have shown that testosterone replacement therapy can improve glycemic control in males with diabetes. However, the mechanisms by which testosterone therapy works are not well understood.
One study examined the effects of testosterone replacement therapy on glycemic control in older, overweight males with type 2 diabetes and hypogonadism. Using the Hines VA Hospital Electronic Medical Record (EMR), researchers tracked the medical records of 1737 males with diabetes and hypogonadism. The study included five years of data from 2008 through 2018. In addition to monitoring the blood glucose level, the participants were also evaluated for several indices related to metabolic syndrome.
Improves visceral adiposity and hypercholesterolaemia
Efforts to improve visceral adiposity and hypercholesterolaemia are essential for preventing atherosclerotic cardiovascular disease (ACVD) and metabolic syndrome. These two conditions are associated with dysregulation of the production of adipocytokines and abnormal glucose metabolism. Several interventions have been used to reduce visceral adiposity. They include calorie restriction, exercise, and diet. These interventions are effective in reducing visceral adiposity, thereby reducing the risk of ACVD. In addition, these interventions can improve hypoadiponectinemia.
Several studies have shown that the presence of visceral adiposity is a strong predictor of cardiovascular disease. This is especially true for subjects from East and South Asian countries. In these countries, there is a familial predisposition for dyslipidemia.
18133 Ventura Blvd Suite C, Tarzana, CA 91356